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PLACEBO EFFECT FOR LOW BACK PAIN: A META-ANALYSIS 
Matthew Lanham 
April 12, 2010 
This study investigates the placebo effect in randomized controlled trials of 
low back pain. This effect has not been analyzed over time or in respect to low 
back pain. A meta-analysis was performed using the Pubmed/Medline database 
for low back pain RCTs with a placebo group. It was shown that in studies using 
the visual analogue scale (VAS) and the numeric rating scale (NRS-11) that 
there is a positive placebo effect. While the VAS mean change appears 
consistent up to 6 months, the limited number of studies available (30, n=1150), 
did not allow certain time periods to be investigated. For NRS-11 (11, n=477), a 
general change was calculated based on the first measurement taken. It was 
established that the expected VAS difference in means was -15.6 (-20.9, -10.2) 
with a p-value < 0.001 and the NRS-11 difference in means to be -1.5 (-2.3, -0.8) 
with a p-value of < 0.001. 
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INTRODUCTION 
The main objective of pharmaceutical companies is to create new and 
improved drugs with minimal side effects that can be marketed to generate large 
revenues. A recent article in Wired Magazine suggests that many of the 
pharmaceutical giants have been struggling to produce new treatments because 
they cannot prove those treatments work (Silberman 2009). When clinical trials 
comparing novel treatments to placebo groups fail to demonstrate superior 
efficacy in the treatment arms, research time and money are lost. One thing that 
is still not completely understood is how participants assigned to the placebo 
group respond positively in many studies when the placebo contains no active 
substance and in many cases is no more than a sugar pill. 
The response to a placebo has been called the "placebo effect" or 
"placebo response." In the literature, these terms have been used synonymously 
with one another even though they are different (Shapiro and Shapiro 1997). 
Since the response observed occurs over time, it is believed in most studies that 
an individual's body will chemically repair itself to some extent. However, the 
effect of natural healing would not be observed unless a third control group 
receiving no treatment was included in the studies. It has been questioned in 
antidepressant trials whether the observed response is actually a regression to 
the mean effect (Rief, et al. 2009). While both of these ideas require 
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consideration, this study will use the terminology placebo effect because there is 
no control arm receiving no treatment. Thus, the entire response will be 
contributed to the placebo effect. However, if a third group was available, effects 
could be partitioned appropriately. In depression trials, natural healing groups are 
rarely used as they are considered unethical (Rief, et al. 2009). 
In 2001, The New England Journal of Medicine published a systematic 
review of studies comparing a placebo to no treatment. It was determined that 
there was a beneficial placebo effect for pain compared to no treatment for 
continuous outcomes which used the visual analogue scale (Hrobjartsson and 
Gotzsche 2001). Twenty-seven out of the 130 trials had pain as the clinical 
condition being investigated and exhibited a standardized mean effect of -0.27 
with a 95 percent confidence interval between -0.40 and -0.15. None of the other 
conditions suggested a statistically significant effect. Interestingly, for pain it was 
observed that as the sample size increased the effect appeared to decline 
(Hrobjartsson, et al. 2001). 
In 2004, the same researchers followed up on their previous review and 
investigated 52 new trials. Their results were consistent with the first review and 
showed that pain had a significant effect with a standardized mean effect of -0.25 
with a 95 percent confidence interval between -0.35 and -0.16 (Hrobjartsson and 
Gotzsche 2004). 
In this study, a meta-analysis is performed to investigate the placebo 
effect in low back pain. Although similar to Hrobjartsson and Gotzsches' study, 
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which studied the placebo effect in general pain, the focus in this study is placed 
on a specific area of pain (low back pain) and the expected effect over time. 
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BACKGROUND AND REVIEW OF THE LITERATURE 
Randomized controlled trials 
Randomized controlled trials are considered the gold standard in current 
medical research. The main reason this approach is considered best practice is 
because it is assumed many biases will be reduced if not eliminated. In addition, 
randomization will likely lead to balanced groups that can be compared 
(Friedman, Furberg and DeMets 1998). Perfectly balanced groups will not often 
occur by randomization, however, they are comparable enough that important 
covariates will not influence or invalidate scientific results. Depending on the 
many possible clinical trial designs, participants could be accrued first, placed 
into one of the treatment groups as they become available, or even switch 
groups after already being assigned to a group (Friedman, et al. 1998). The point 
is to have evenly balanced groups where one group receives the intervention and 
another group receives the control. 
4 
Placebos 
Many times there is only one intervention being tested against a control 
group. The control group may be assigned to a placebo or "sham" therapy if no 
other generally accepted best intervention is available. However, even then a 
passive control might be ethically used if the current standard treatment has 
many side effects (Friedman, et al. 1998). There has been much ethical debate 
on when and how to use a placebo as control therapy. Since the Declaration of 
Helsinki was adopted in 1964 to address ethical human rights issues, specifically 
protection of clinical trial subjects, much debate over the terminology has been 
expressed in the literature (Smoak 2004). A revision was made to the Declaration 
of Helsinki in 2000 regarding the use of placebo controls and is quoted as 
follows: 
"The benefits, risks, burdens, and effectiveness of a new method should 
be tested against those of the best current prophylactic, diagnostic and 
therapeutic methods. This does not exclude the use of placebo, or no 
treatment, in studies where no proven prophylactic, diagnostic or 
therapeutic method exists (Smoak 2004)." 
Providing full informed consent about alternative therapies while allowing minimal 
discomfort to participants tends to be the ethical consensus among practitioners 
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and investigators in how to employ placebo controlled trials (Ellenberg and 
Temple 2000). 
Placebos have been shown to provide improvement when there is no inert 
benefit to them. The definition of placebo in the literature has transformed over 
time. Many have stated the first appearance of placebo was a mistranslation into 
Greek from the ninth verse of Psalm 116 in the Hebrew bible (Lasagna 1986, 
Finniss, Kaptchuk, Miller and Benedetti 2010). The Hebrew version stated, "I will 
walk before the lord", but "I will walk" was translated to "placebo", which meant "I 
will please." Placebos were defined in various ways in the medical literature in 
the eighteenth century. They were described as "a common method of medicine," 
"calculated to amuse for a time," as well as "make-believe medicine" (Lasagna 
1986). Placebo has occasionally been cited by British authors as a dummy 
control. Gaddum suggested they should be called dummies in a 1953 lecture on 
clinical pharmacology, stating "This seems to me the right word to describe a 
form of treatment which is intended to have no effect and I follow those who use 
it (Beecher 1955)." In Shapiro's book, The Powerful Placebo, an updated 
definition of placebo must satisfy three criteria: 
"A placebo is any therapy (or that component of any therapy) that is 
intentionally or knowingly used for its nonspecific, psychological, or 
psychophysiological, therapeutic effect, or that is used for a presumed 
specific therapeutic effect on a patient, symptom, or illness but is without 
specific activity for the condition being treated. A placebo, when used as a 
control in experimental studies, is a substance or procedure that is without 
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specific activity for the condition being treated. The placebo effect is the 
nonspecific psychological or psychophysiological therapeutic effect 
produced by a placebo." (Shapiro, et al. 1997) 
Henry Beecher's article, "The Powerful Placebo", published in the Journal 
of the American Medical Association in 1955, is probability one of the most 
famous articles to discuss the idea of the placebo effect and has been referenced 
many times in the literature. After investigating 15 studies which used placebo as 
the control, Beecher concluded the average placebo effectiveness was 35%. For 
pain the effectiveness was 30%, where improvement was considered if pain had 
decreased by more than half (Beecher 1955). 
Pain Measurement 
Reducing biases by a properly designed randomized controlled trial will 
improve the likelihood that study results are valid. However, randomized 
controlled studies assessing an effect or change in pain have encountered 
difficulties. Unlike measuring heart rate or blood pressure, there is no instrument 
or device to record a pain level the exact same way on every individual. The only 
way to gauge pain subjectively is to have each individual express what they 
consider to be their pain level (Hartrick, Kovan and Shapiro 2003). There have 
been several commonly used pain scales in the literature, but the most widely 
used scales are the visual analogue scale (VAS) and the numeric rating scale 
(NSR-11). These measurements are specific to pain, while many others involve 
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multiple questions, which together are thought to gauge pain or function. Having 
multiple scales has irritated some investigators. In a 1998 issue of Spine, Oeyo, 
et al. said, 
"Even when studies are concordant in demonstrating benefit for a given 
treatment, differences in outcome measures may make it difficult to 
assess the relative magnitude of treatment effects among various studies. 
This may make it difficult or impossible to pool the results of multiple 
studies in the form of a meta-analysis.(Oeyo, et al. 1998)" 
The visual analogue scale (VAS) was originally most widely used to obtain 
subjective measurements in the fields of education and psychology (Seymour, 
Simpson, Charlton and Phillips 1985). In the 1970s, researchers began using it 
as a measurement for pain. It has been shown to be a validated ratio measure 
for chronic and experimental pain (Price, McGrath, Rafii and Buckingham 1983). 
In mild to moderate pain, VAS has shown linearity (Hartrick, et al. 2003). 
The VAS is shown as either a vertical or horizontal line with common 
lengths typically of 100mm or 10 mm. However, lengths of 5, 15, and 20 mm 
have been used in dental research (Seymour, et al. 1985). The beginning of the 
line is typically labeled "no pain" with the end-phrase cited in various manners 
such as "very severe pain", "worst pain imaginable", "extreme pain", or "pain 
cannot be worse" (Seymour, et al. 1985, Breivik, Bjornsson and Skovlund 2000, 
Gould 2001, Sheldon, Bird, Smugar and Tershakovec 2008). The individual 
would then draw a vertical mark (horizontal scale) or horizontal mark (vertical 
scale) expressing where their pain would lie on the scale. It has been expressed 
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in the literature that different extreme labels might cause a subjective bias but 
should still be used and clearly labeled (Sriwatanakul, et al. 1983). In addition, 
any extreme value could be considered immeasurable as there is no inherent 
absolute value, leading to a subjective interpretation to the patient drawing the 
line (Wewers and Lowe 1990). 
o 
No rain 




The numeric rating scale (NRS-11) is a whole number scale that ranges 
from 0 to 10, with 0 indicating "no pain" and 10 indicating "worst pain possible". 
However, like the VAS, extreme labels have been shown in other forms. An 
individual will choose one of the eleven choices indicating the pain they are 
experiencing (Hartrick, et al. 2003). This scale is used often by clinical 
investigators due to its easy application. 
It is important to note that VAS and NRS-11 outcomes are not exactly 
equivalent to one another. While VAS is a ratio measure, NRS-11 has not shown 
these characteristics consistently. A linear relationship has been shown to exist, 
but the consistency of the slope is not uniform (Hartrick, et al. 2003). 
1 http://z.about.com/d/backandneck/1/0/m/2Nisual-Analog-Scale-VAS. gif 
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Currently, there are many questionnaires to asses functionality related to 
back pain. Some of the most well established questionnaires are briefly detailed 
by Kopec and include the Oswestry Low Back Pain Disability Questionnaire 
(ODQ), Million Visual Analogue Scale (MVAS), Roland-Morris Disability 
Questionnaire (RMDQ), Waddell Disability Index (WDI), Low Back Outcome 
Score (LBOS), Clinical Back Pain Questionnaire (CBPQ), Low Back Pain Rating 
Scale (LBPRS), Quebec Back Pain Disability Scale (QBPDS), North American 
Spine Society Lumbar Spine Questionnaire (NASS LSQ), and Resumption of 
Activities of Daily Living Scale (RADL) (Kopec 2000). There are other 
questionnaires or modifications to these questionnaires that have been used or 
proposed. 
Meta-Analysis 
An approach used to combine and analyze quantitative results from 
several related studies using statistical methods is called meta-analysis (Littell, 
Corcoran and Pillai 2008). The first recorded meta-analysis was performed by 
Karl Pearson in 1904 when he investigated the effectiveness of a Typhoid 
vaccine by combing 11 studies. Sir Ronald Fisher has also been credited for 
contributing to the ideas of meta-analysis by indicating that underpowered 
studies (i.e., ones with small sample size) will likely fail to reject the null 
hypothesis, but combining the smaller studies into one larger study will increase 
the cumulative power for the test under consideration (Cooper 2010). These 
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ideas of combining studies, termed narrative review or systematic review, did not 
gain acceptance in research until the 1970s when used predominately in the 
fields of psychology and education (Cooper, Hedges and Valentine 2009). 
Narrative reviews have been used to combine studies and draw 
conclusions from them. The main concern with narrative reviews is that they are 
more prone to subjective bias in the way the conclusions are drawn. This is 
because they do not inherently use standardized techniques and methods to 
derive an overall unbiased result to the research question. 
Systematic reviews on the other hand, have a less subjective way in which 
studies are found, and are aimed at reducing biases by having a defined protocol 
before the start of the study. The protocol clearly defines the inclusion-exclusion 
criteria to reduce subjectivity in which studies are actually used in the analysis 
(Borenstein 2009, Cooper, et al. 2009). Systematic reviews have been referred to 
as meta-analyses. These ideas do have differences, but are commonly used in 
conjunction with one another as is typically the case today. 
While systematic reviews detail the method of data collection in a more 
objective manner, meta-analysis is the statistical method used to analyze the 
data (Borenstein 2009). In many cases, this might be to simply generate an effect 
size between variables. However, meta-analyses also investigate the 
consistency and dispersion of the effects included in the analysis (Borenstein 
2009). 
Some of the most noted issues expressed about meta-analysis are 
inconsistent outcomes, model uncertainty, missing data, and publication bias. 
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Since each study is investigating a possibly different population and outcomes 
are presented in various manners, pooling the data might lead to inconsistent 
outcomes (Stangl and Berry 2000). Furthermore, it is important to use an 
appropriate model when combining results. Fixed and random-effects models 
have different assumptions about the effects and the between- or within-study 
variances (Borenstein 2009). Therefore, it is critical that the model chosen 
matches the distribution of effect so the errors are accounted for appropriately. 
Data can be missed when studies were not included in the meta-analysis 
because they were either not found or not available to researcher(s). Moreover, 
studies that have met all the inclusion criteria and do not report required data 
needed for the meta-analysis study are excluded (Stangl, et al. 2000). 
Publication bias occurs when the included sample collected from 
published studies is not representative of the entire collection of studies 
performed (Rothstein, Sutton and Borenstein 2005). In an amusing editorial 
published in Science in 2004, Don Kennedy was quoted as saying, 
"Look, journals and scientists like positive results and get disappointed by 
negative results. So there's a problem - al/ the unpublished negative 
results lurking in those file drawers!" Thus, the fly in the meta-analysis 
ointment: It's likely that aggregated results from published papers 
constitute a biased sample (Kennedy 2004)." 
After considering the known limitations about meta-analysis, there is still light at 
the end of the tunnel. 
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When different measures are used across studies, there are statistical 
transformations that allow for their combination (Bax, Yu, Ikeda, Tsuruta and 
Moons 2006, Borenstein 2009). In addition, when combining outcomes, 
heterogeneity amongst studies should always be investigated. In doing so, the 
researcher will be able to determine if the different populations per study have 
different variation in the effect sizes (Borenstein 2009). 
Model specification should typically be decided upon before the study 
begins. Since the question(s) to be addressed are understood before the meta-
analysis protocol is implemented, all data obtained is expected to have identical 
studies, thus employing the fixed-effects model, or similar studies, requiring the 
random-effects model (Stangl, et al. 2000, Borenstein 2009). A more detailed 
discussion of the differences between these models is found in the statistical 
methods section of this paper. 
Publication bias has been the most noted drawback to performing meta-
analyses. For example, if one is trying to produce a quantitative synthesis of the 
literature and the observations (studies) are biased and not representative, then 
the validity of the results are questionable (Rothstein, et al. 2005). Fortunately, 
there have been statistical methods to identify and assess if publication bias is 
present. The latest methods include funnel plots, failsafe N, trim and fill method, 
and cumulative effects forest plots (Rothstein, et al. 2005). 
After having received much criticism over the years, meta-analysis 
appears to be more accepted and has been implemented in many fields of 
research. PubMed classified approximately 12,000 publications as meta-
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analyses between 1990 and 2005 with an increasing yearly trend (Sax, et al. 
2006). Meta-analysis has posed new questions and called people of all fields to 
consider new ways to make unpublished data available. An example is the 
foundation of the Placebo Response Drug Trials Survey, which is examining 
several years of clinical trial data to try and pinpoint which variables, if any, are 
significant to the placebo effect (Silberman 2009). 
Lastly, some meta-analyses have tried to add another layer of quality 
assessment to the analysis by using journal rating scales. The idea is that using 
studies from highly cited journals will yield a higher quality assessment of the 
literature. In fact, it has been shown that the frequency of citations for medical 
journals is consistent with journal quality ratings rated by researchers and clinical 
practitioners (Saha, Saint and Christakis 2003). Having found a rating scale that 
is relevant to the included studies will typically encompass the analyst or 
researcher to assign a quality score to each article which will serve as a weight. It 
has been determined that quality scales will help with maintaining consistency in 
those using the scale, although various scales can lead to completely different 
results. Thus, choosing a particular scale will still imply another layer of 
subjectivity (Cooper 2010). Since many investigators have used quality scores in 
their meta-analyses for weeding out or weighting down poor quality studies, the 
technique should not be abandoned. However, the consensus among meta-
analysis methodologists is to assess worth on a study-by-study basis rather than 
summing up quality via journal quality scores (Littell, et al. 2008). This ideology is 
used in this analysis. 
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The organizations most well known for performing systematic reviews and 
meta-analyses is the Cochrane Collaboration. This international organization 
includes over one hundred countries and several thousand contributors that 
create systematic assessments, termed "Cochrane Reviews", of all possible 




The data used in this study was collected by searching Medline/Pubmed. 
PubMed is provided by the United States National Library of Medicine and 
National Institutes of Health as a free way to access the MEDLINE database, 
which encompasses around 19.5 million citations on biomedical and life science 
topics (Wikipedia). Thus, it is believed this database will provide a 
comprehensive, while not entirely exhaustive retrieval of studies on this topic. 
Only low back pain studies will be assessed, thus excluding studies 
focusing on other bodily regions such as the neck or leg. Any study design that is 
not a randomized controlled trial will be excluded since randomized controlled 
trials are considered to be of the highest quality due to reduced biases. Each 
study must have a control group assigned to placebo or a sham therapy. Control 
groups using lower doses of an intervention, alternative therapies, educational 
programs, standard care or any other therapy that is not expressed as placebo or 
sham therapy will be excluded. 
The search key words used were: "low back pain or LBP" and 
"randomized clinical trial or randomised clinical trial or randomized controlled trial 
or randomised controlled trial or RCT" and "placebo or control group or control". 
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The type of article was limited to clinical trial or randomized controlled trial 
or clinical conference or clinical trial phase I or clinical trial phase II or clinical trial 
phase III or clinical trial phase IV or controlled clinical trial or multicenter study. 
Species was restricted to humans and publication date was restricted 
between 01/01/2000 to 03/01/2010, or approximately the last 10 years. 
This search is believed to have the appropriate balance to not allow any 
relevant studies to be missed, while filtering out obvious non-relevant studies. 
The search is limited to approximately the last 10 years to collect enough studies 
to investigate any possible effects found while reducing any possible 
confounders from different treatment time eras. 
Statistical Methods 
Data obtained may come in many effect size forms, such as paired pre-
and post-treatment means with standard deviations, paired group differences, 
correlations amongst effect sizes, etc. Having any of these will allow 
standardized transformation to the others. All studies included will have matched 
paired groups where baseline and follow-up statistics are derived from 
dependent groups. 
Paired group means (Xbaseline,Xtollow-uP) with standard deviations 
(Sbaseline,StolloW-UP) and sample size n at baseline and post-treatment times are 
expected to have the highest frequency as they are basic summary quantities 
easily calculated. Some studies will have multiple follow-up measurements such 
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as post-treatment, 1-month, or longer, while some will just have one following 
treatment. 
To compute the raw mean difference (0) and standard error (SE) for each 
follow-up time period equation (1) and (2) will be used: 
Equation 1: 
Equation 2: SEw = 
S[baseline +sf - 2r S i,baselineS i 
n 
(Borenstein 2009) 
where i is the ith follow-up time and n is the number of observations in the study. 
The sample correlation r in this context is a linear measure of association 
between the baseline and post-measurements. The correlation will range 
between minus one and one, where closer to one would indicate a higher 
positive dependency between the variables, whereas a negative correlation 
would indicate a high negative dependency. A correlation near zero suggests a 
lack of linear relationship (Rosner 2005). The sample correlation between two 
variables is found by equation (3): 
Equation 3: (Rosner 2005) 
where i is the number of pre- and post-mean measurements and Sx is the 
standard deviation of the baseline measurements, Sy is the standard deviation of 
the post-measurements, and n is the number of observations being compared. 
If the pre-post correlation is not available from the studies, there are 
several options available. In a meta-analysis investigating the comparative 
effects of postoperative analgesic therapies, Ballantyne tried a range of 
correlations (0, 0.25, 0.50, and 0.75) to gauge the impact it would have on the 
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standard error (Ballantyne, et al. 1998). This parameter is important because if 
the effects are computed assuming independence (p = 0) when they are not, the 
standard errors will be overestimated (Dunlap, Cortina, Vaslow and Burke 1996). 
It has been shown that p may change over time as well as differ for various 
studies making it unfeasible to obtain a p that is not somewhat biased for some 
of the included studies. There are many suggestions on how to pick a p to use 
when it is not available (Morris and DeShon 2002). In this study a correlation will 
be derived from pre-post means and compared to a more conservative estimate 
to investigate how p changes the standard error of the mean effects. 
Using raw difference in means effects is preferred when the outcome 
measures are based on the same scale across studies (Borenstein 2009). In this 
study, the raw difference in effects is suitable. However, standardized difference 
in means will also be computed to allow for measurements such as correlations 
among differences to be included into the meta-analysis. As stated previously, 
some obtained effects can be included and transformed to a standardized effect. 
Standardized measures will also allow comparisons to the general pain effect 
found in the Hrobjartsson and Gotzsches' study, as well as to allow comparison 
of the VAS and NRS-11 results. Another benefit of standardization here will allow 
for better comparability among the scales as subjective biases of the VAS and 
NRS-11 end labels have been noted 0Newers, et al. 1990). 
The standardized mean difference (d) is found by taking the raw difference 




Equation 4: (Borenstein 2009) 
St,baseline +S[ -2rS i.baselineSi 
2(1-r) 
where i is the ith follow-up time. The standard error of the standardized mean 
difference is found accordingly in equation (5): 
Equation 5: SEid = J(~ + ::) * 2(1 - r) (Borenstein 2009) 
An example where pre- and post-measurement data are used to derive 
the raw mean difference, standard error, as well as the standardized mean 
difference, and standard error is shown below using data in Table 1. 
Table 1: Example using paired pre-post measurements (means, sds, n) 
Measurement Baseline Baseline Follow-up Follow-up Pre-Post Sample 
Study Times Mean SD Mean SD Correlation Size 
Study A 1 week 63.7 7.7 35.0 13.2 0.34 * 15 
Study A 2 weeks 63.7 7.7 31.0 7.6 0.34 * 15 
* ThiS value was not available thus a genenc value was used for presentation 
Using equations (1) and (2) described previously, the raw mean difference 
and standard error is found for each follow-up time: 
Dl week = 35.0 - 63.7 = -28.7 SED•1 week = 
D2 weeks = 31.0 - 63.7 = -32.7 SED•1 week = 
7.72 +13.22-2(0.34)(7.7)(13.2) = 3.31 
15 
7.72 +7.62-2(0.34)(7.7)(7.6) = 2.27 
15 
Using equations (4) and (5) the standardized mean difference and 
standard error is found for each follow-up time: 
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-28.7 
d1 week = 7.72+13.2L2(0.34)(7.7)(13.2) = -2.57 
>/1-0.34 
SEd,l week = (~) + -2.57
2 J2 * (1 - 0.34) = 0.62 
15 2*15 
-32.7 
d2 week = 7.72+7.6L2(0.34)(7.7)(7.6) - -4.27 
>/1-0.34 
SEd,2 week = (~) + -4.272 J2 * (1 - 0.34) = 0.94 15 2*15 
Paired group differences (D) with the standard deviation of the differences 
(Sdiff) is sometimes reported instead of the pre-post measures and standard 
deviations detailed previously. In this case the raw mean difference is already 
reported, so the standard error of this estimate will be obtained using equation 
(6): 
Equation 6: SE. = Sdiff lD rn (Borenstein 2009) 
where n is the sample size for that follow-up time. 
Standardized mean differences are then found the same way as stated in 
equations (4) and (5). A numerical example of paired differences using equations 
(4), (5), and (6) is shown below using Table 2 data. 
Table 2: Example using paired mean measurement (mean diff, sd of diff, n) 
Measurement Mean SD of Sample Pre-Post 
Study Time Difference Difference Size Correlation 
Study B 1 week -18.5 21 63 0.34 * 
* ThiS value was not available thus a genenc value was used for presentation 
Dl week = -18.5 SE .E... = 2.65 D,l week = ..[63 
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-1.01 SEd,l week = (2.) + -1.01
2 .J2 * (1 - 0.34) = 0.18 
63 2*63 
In the previous example discussing the paired group standard deviations it 
might happen that a standard deviation is not reported. Instead a one-sided or 
two-sided p-value is provided with the sample size. To back compute to obtain 
the paired difference standard error use equation (7): 
Equation 7: SE - IDii iD - -t- (Borenstein 2009) 
where t is the student's t-distribution for the reported p-value and the degrees of 
freedom, which equal n minus 1. 
The standardized difference in means for each follow-up time and 






(1) ~ SEid = rn ..J1 + -t 
where n is the sample size for that follow-up time i. 
(Borenstein M 2009) 
(Borenstein M 2009) 
A numerical example of this situation is illustrated below in Table 3 using 
equations (8) and (9). 
Table 3: Example using mean difference and p-value (mean, n, p-value, tails) 
Measurement Mean Sample Paired groups 
Study Time Difference Size p-value Tails 
Study C 1 hour -7.0 20 0.055 2 
Dl hour = -7.0 
1-7.01 
SED 1 hour = -- = 3.42 , 2.045 
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where 2.045 is found from a t-distribution with a two-sided p-value of 0.055 and 
19 degrees of freedom. 
2.045 f(1) I -0.462 
d1 hour = m = -0.46 SEd ,l hour = ~ \2"0) -'./ 1 + -2 - = 0.24 
Lastly, the correlation (r) amongst change levels with sample size (n) will 
be expressed. While there are many more possible conversions that can be 
performed given the available data obtained, they will not be addressed here. 
Refer to the reference manual provided with the software, Comprehensive Meta 
Analysis (Version 2) for all possible situations (Borenstein M 2009). 
The correlation can be used as a standardized effect size. The reason for 
this is that the correlation is a standardized measure. Like previous correlations 
discussed, the correlation in this context is the actual correlation between pre-
and post-measurement follow-up times. However, nothing else is known besides 
the sample size. The raw mean effect cannot be obtained from the data because 
there is not enough information to back compute. Equations (10) and (11) are the 
formulas to obtain the standardized mean difference as well as the standard 
error. 
Equation 10: d·=~ 
I ,./l-r2 (Borenstein M 2009) 
It follows that the standard error is obtained by: 
Equation 11: (1) ~ SEid = >In ~ 1 + -t (Borenstein M 2009) 
A numerical example of this situation is illustrated below in Table 4 using 
equations (10) and (11). 
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Table 4: Example using correlation among effects (r, n) 
Measurement Sample 
Study Time Correlation Size 
Study D 1 month -0.36 21 
d = 2*(-0.36) = -077 
1 month .J 1-( -0.362 ) • SEd,l month = 
Once all effect sizes have been obtained, Hedge's g is calculated by 
adjusting the standardized mean differences. Hedge's g is used to adjust for 
small sample biases. The correction bias adjustment (J) was found to reduce 
upward standardized mean difference bias in studies with less than 20 
observations (Littell, et al. 2008). The correction factor has also been termed the 
d-index (Cooper 2010). Hedge's g is achieved by simply multiplying J to each di , 
where J is found in equation (12): 
Equation 12: 
3 
] = 1- 4df-1 (Borenstein 2009) 
where the degrees of freedom equal n minus one. 
Once effect sizes have been adjusted for any biases, a summary effect 
and confidence interval can be obtained. However, the appropriate model to 
derive a summary effect must first be specified. Two options are available, a 
fixed-effects model or random-effects model. 
In most meta-analyses a random effects model is employed instead of a 
fixed-effects model. This is because all the studies included are not getting the 
same placebo type for the same length of time. The distribution of true effects will 
be assumed to be sampled from the distribution of effects rather than a common 
effect (Borenstein 2009). A fixed-effect model might be considered if grouped by 
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placebo type and if time periods were the same. Then all the error between 
studies could be contributed to sampling error only, and a common effect could 
be assessed. However, in this analysis using the random-effects model the 
estimate is actually an average of the distribution of effects which includes 
sampling error and between-studies error (Borenstein 2009). Having the 
additional between-studies error will lead to different overall summary mean 
effects because the weight assigned to each study will be different than using the 
fixed-effect model. This will be detailed once the concept of heterogeneity is 
described as the calculations go hand-in-hand. 
The presence of heterogeneity is investigated in order to assess the 
similarity among the studies, or more explicitly indicating similarity in effect sizes. 
The Q and [2 statistics are used to identify and assess the heterogeneity in the 
data. The Q statistic is a standardized statistic that allows a test of the null 
hypothesis that the studies included are homogeneous. Formally, this is: 
Ho: Studies have common effect size (Homogeneity) 
Hi: Studies do not have a common effect size (Hetereogeneity) 
Q is a ratio measure of the observed variation compared to the within-study error 
(Borenstein 2009). Once Q is obtained, it is compared to a chi-squared 
distribution based on the degrees of freedom, which is the number of studies (k) 
minus one. A p-value less than the stated significant level, typicallya = 0.05, 
would lead to the rejection of the common effect size hypothesis in favor of the 
heterogeneity alternative. 
The Q statistic is computed as shown in equation (13): 
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Equation 13: (Borenstein 2009) 
where Wi is the weight assigned to each study. The weight used is one divided 
by each respective studies variance 2:... ~ is the unbiased effect size per study, 
Vi 
denoted by Hedge's g discussed previously. It can be seen from equation (14) 
why this form of the equation is also referred to as a standardized weighted sum 
of squares (Borenstein 2009). 
Equation 14: (Cooper 2010) 
The mean effect M is shown in equation (15): 
Equation 15: (Borenstein 2009) 
Lastly, Q allows a formal test of homogeneity based on effect sizes. It is 
not an assessment of the amount of heterogeneity among the studies. One 
should expect that a larger Q with a small number of studies will likely lead to the 
rejection of the null hypothesis, but that by itself does not imply consistency 
among the effect sizes. 
Another statistic used in investigating heterogeneity is the [2 statistic. [2 is 
the assessment of how much heterogeneity is present, and unlike the Q statistic, 
[2 is not dependent on the number of studies (k). It gives a descriptive statistic of 
the percentage of true heterogeneity versus combined observed variation. It is 
found by using equation (16): 
Equation 16: (Borenstein 2009) 
where degrees of freedom is equal to k minus one. 
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Larger values serve as an indicator that the variations observed are real. 
However, this does not mean that the dispersion among studies is a wide range. 
The most intuitive way to understand what the [2 statistic is describing is by 
looking at percentage of overlap in the confidence intervals, which is influenced 
by the width (Borenstein 2009). The more overlap the less variation among the 
studies. 
The statistic, r2 is used in the study weighting to account for the between-
studies variance in the random-effects model. As described previously, the fixed-
effect model assumes only random sampling error in which the weight assigned 
to each study would only be 2., whereas the random-effects model assigns a 
Vi 
total weight of ~ to each study to account for the between-studies error 
Vi+T 
(Borenstein 2009). r2 is computed from equation (17): 





It can be seen that r2 uses the heterogeneity Q calculation, which 
measures the observed variation compared to the within-study error. When this is 
used as a ratio versus a measure of the weights an estimate of the variance of 
true effects is obtained (Borenstein 2009). 
After investigating heterogeneity among the effect sizes and looking at the 
between-studies variance the random-effects model is employed directly to 
derive a combined summary effect and standard error. 
M* is known as the random-effects mean effect and is derived by the ratio 
of the sum of weighted differences to sum of weights shown in equation (18): 
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Equation 18: (Borenstein 2009) 
where wt = ~ which was discussed previously, and Yi is the biased-adjusted 
Vi+T 
Hedge's g standardized effect. 
Ninety-five percent confidence intervals for the summary effect will be 
performed in the study and are found by using equation (19). 
Equation 19: M* ± 1.96* ~ 
...jLf=l wt (Borenstein M 2009) 
A numerical illustration using the previous standardized effect examples is 
detailed below. 
Table 5: Example of computing summary effect M* 
Measurement Sample size Hedge's g 
Study Time d SEd n or Y SEq 
Study A Post-treatment -2.57 0.62 15 -2.43 0.58 
Study A 1 week -4.27 0.94 15 -4.04 0.89 
Study B 1 week -1.01 0.18 21 -1.00 0.18 
Study C 1 hour -0.46 0.24 20 -0.44 0.23 
Study 0 1 month -0.77 0.51 21 -0.74 0.49 
Computing the Hedge's g and standard error for Study A post-treatment 
follow-up time is shown as follows: 
9 = d * ] = -2.57 * ( 1 - 4(14~ _ 1) = -2.43 
SEg = SEd * ] = 0.62 * (1 - 4(14~ _ 1) = 0.58 
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Table 6: Example of numerical calculations 
Study Yorg V y W W 2 Wxy2 WxY W*xY '[2 VTotal W* 
Study A -4.04 0.89 1.12 1.25 18.29 -4.53 -2.15 0.99 1.88 0.53 
Study A -2.43 0.58 1.72 2.95 10.16 -4.18 -1.55 0.99 1.57 0.64 
Study B -1.00 0.18 5.69 32.34 5.69 -5.69 -0.86 0.99 1.16 0.86 
Study C -0.44 0.23 4.43 19.65 0.85 -1.95 -0.36 0.99 1.21 0.82 
Study D -0.74 0.49 2.06 4.25 1.13 -1.53 -0.50 0.99 1.47 0.68 
Sums 15.02 60.45 36.12 -17.86 -5.42 3.53 
Using the Table 6 data calculations, the heterogeneity measures Q and [2are 
found as follows: 
I
n ("'~ ~. 11:)2 -17.862 
Q = u'l.(vl.2) - 4..l=~ 1 .l 3612 1487 VI', I, '" =. - 60.45 = . 
i=l 4..i=l Wl 
(
Q - df ) (14.87 - (5 - 1)) 
[2= Q *100% = 14.87 *100%=73.11% 
The between-studies error '[2 is computed as follows: 
'[2 = __ Q_-_d_f_---". 
",n ~. _ Z:f=l W/ 
4..i=l 1 "'~ W. 
4..l=l 1 
= 
14.87 - (5 - 1) 
1502 _ 60.45 
. 15.02 
0.99 
Lastly, the overall summary effect and a 95 percent confidence interval can be 
obtained, where W* = _1_: 
VTotal 
M* = z:~=O wt * Yi = -5.42 
Z:~=O wt 3.53 
-1.45 
-1.45* ± 1.96 * J 1 = (-2.25, -0.66) 
3.53 
Once summary effects and heterogeneity have been addressed, variability 
will be examined using forest plots. Forest plots allow studies to be compared 
visually on an individual basis. Plots used in this analysis will have the effect per 
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study shown as a box, sized by the weight that is contributed to the overall 
summary effect as shown in Figure 2. Each study will have a line to indicate a 95 
percent confidence interval for that study. The overall summary effect will be a 
diamond whose width is the 95 percent confidence interval for the summary 
effect. 
Figure 2: Forest Plot Example 
Study nam. Time point Statistics for enh study Std din In means and 95% CI 
ltd dlff StanCiard Lower Upper 
In means error Variance limit limit Z-Value p-Value 
Study A 1 week -4274 
Study A 1 Post~treatment -2572 
StudyB 1 week -1 012 
Study C 1 hour -0457 
Study 0 1 month -0772 
-1453 
0944 0892 -6125 -2423 -4.526 0.000 
~ 
0616 0379 -3778 -1365 -4177 0.000 
0178 0032 -1361 -0663 -5.686 0.000 
0.235 0055 -0918 0003 -1945 0052 
0505 0255 -1 762 0219 -1527 0127 
0407 0.165 -2250 -0656 -3573 0.000 
".00 04.00 0.00 4.00 8.00 
Positive Effect Negative Effect 
Tho PlKebo Effect in Low Back Pain: A Met. AnoJtpie 
Forest plots have been used since the 1970s to visualize study variability, 
but were not used to generate a summary effect until a meta-analysis was 
performed in 1982. Forest plots have also been referred to as "Forrest" plots in 
regard to Pat Forrest who used them in breast cancer research. However, the 
actual name stems from the appearance of the plot where it appears to be a 
forest of lines (Lewis and Clarke 2001). 
Next, publication bias methods used in this analysis will be discussed. 
These methods include the funnel plot, trim and fill algorithm, failsafe N, and 
cumulative effects plot. 
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The concept of publication bias suggests smaller studies with non-
significant results are less likely to be published than larger studies with 
significant results. Moreover, medium-sized studies with significant results are 
more publishable than medium-sized studies with non-significant results 
(Rothstein, et al. 2005). The funnel plot is the ideal method to investigate this 
idea. 
The use of the funnel plot is to help identify if the included studies are 
representative of the target population. This is presumed to be the case if the 
studies are equally distributed about the overall computed effect size (Borenstein 
2009). If the studies are not symmetric, this suggests the sample used is biased. 
These plots are rather novel in nature, but highly effective at investigating to see 
if small study effects are present (Rothstein, et al. 2005). 
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Figure 4: Example funnel plot (Missing values expected to the right of the mean) 
Funnel Plot of Standard Error by Std diff in means 
0.0 
0.2 
Observed studies 0 
• Imputed studies <> Summary effect 









-5 -4 -3 -2 -1 0 2 3 4 5 
Std diff In means 
32 
Figure 3 is a funnel plot using the example data. The funnel plot has the 
standardized mean difference on the horizontal axis and the standard error on 
the vertical axis. The standard error per study is a function of sample size so this 
plot will help detect if smaller studies lead to larger or smaller effects compared 
to larger studies, where the standard error is smaller. Opened circles denote the 
observed studies. In this case there are five, where black circles are imputed 
studies from the trim and fill algorithm. (This algorithm will be discussed below.) 
The standardized difference in means summary effect is a white diamond with 
width shown as a 95 percent confidence interval. The black diamond is the 
standardized mean difference summary effect once observations are imputed. 
The triangle shown is the funnel where the top has a small standard error and 
funnels out as the standard error increases and effects widen. Larger studies 
would be expected to be toward the top where smaller studies toward the bottom. 
The end result is hopefully observed studies scattered randomly but 
symmetrically around the overall effect where the vertical line is drawn 
(Rothstein, et al. 2005). Several studies toward the bottom of the plot and not 
scattered on both sides of the line suggest the sample obtained might be biased. 
Of course there is no way to know for sure if a sample is biased without having 
all the unpublished articles. However, if those articles were available this issue 
would not be investigated to begin with (Borenstein 2009). This approach serves 
as a starting point to investigate possible biases. 
The funnel plot began in educational research in the early 1980s and was 
used sparingly in the research literature until 1988 when Begg and Berlin 
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discussed the issue of publication bias and how funnel plots were useful for 
detecting such biases (Rothstein, et al. 2005). Today, funnel plots are widely 
used and expected when performing meta-analyses. 
Once the funnel plot is generated the trim and fill algorithm can be used. It 
works by moving the small studies with the most extreme effects to the other side 
of the line depending on which direction publication bias is expected to come 
from, in an iterative process until the funnel plot becomes symmetric (Borenstein 
2009). If the plot becomes symmetric, the new estimate of the effect should be 
compared to the original. In Figure 3 the trim and fill algorithm ran assuming 
missing studies from the left of the mean. Since there is no way to move any 
values from the right side of the line to the left side to make it more symmetric 
there were no imputed studies in this case. Thus having no imputed values 
causes the imputed effect to be identical to the original summary effect. In 
Figure 4 the expected missing values are believed to be from the right so 
imputations are moved from the left side of the line to the right side until 
symmetry is achieved. In this case the imputed summary effect has shifted to the 
right. The main idea for imputing smaller studies to one side or the other until 
symmetry is achieved serves as a sensitivity analysis to see what the overall 
impact would be for having such studies excluded (Rothstein, et al. 2005). Since 
the imputed summary effect is close to the original effect we could conclude that 
publication bias is not completely invalidating the summary effect (Borenstein 
2009). 
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Lastly, the imputed summary effect will be reported in this analysis in 
addition to the original summary effect. However, effect conclusions should not 
be based on the imputed effect. Rather, reporting both values just serves as a 
way to describe how sensitive the results are in such studies were to be included 
(Rothstein, et al. 2005). 
The failsafe N is most widely known as the "file drawer" problem (Hartung, 
Knapp and Sinha 2008). This method was developed by Rosenthal in the late 
1970s and is based on combining p-values from the included studies. The 
premise with this technique is studies with statistically significant results are more 
likely to be published than ones with less significant results. Thus resulting in 
more articles left in the researcher's file drawer (Rothstein, et al. 2005). The 
failsafe N estimates the number of non-statistically significant studies required to 
make the summary effect non-significant. It is computed as follows: 
Equation 19: (Rothstein, et al. 2005) 
where N is the failsafe N, k is the number of studies obtained, Zs is the Z-value 
for the observed studies, and Za is the Z-value at the level of significant tested. If 
performing a one-tailed test at a = 0.05, the one-tailed Z-value is 1.645, while a 
two-tailed Z-value is 1.96. 
It will be expected that Zs will be greater than Za, so the question is how 
many more studies at Zi would need to be added to makeZs = Za. Also, the 
failsafe N is not affected by the number of studies or participants reported in the 
study. It is just compared directly the overall Zs value (Rothstein, et al. 2005). 
Large values for the failsafe N are common in the literature. Rosenthal's own 
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research had 94 articles which had a failsafe N of 3263, while others having 
studies as low as eight had an N of 538, and thirteen studies had an N of 22,419 
(Rothstein, et al. 2005). 
Thus even though this method has had wide use and is typically reported 
in meta-analyses, other methods should be incorporated as well. A numerical 
example is shown below using the data in the previous calculations, and Za is 
assumed to be two-sided. 
yields [ 799] 2 
~ 5 ~ - 5 => 79 studies 
1.96 
The fail-safe N is 79, meaning there would need to be 79 excluded studies 
included in the study before the p-value would become non-significant at the five 
percent alpha level. 
The cumulative effects plot is used to investigate the presence or absence 
of publication bias in this analysis. The cumulative effects plot includes studies 
based on a chronological order (Borenstein 2009). As each study is included the 
summary effect and confidence interval should converge and not show any 
noticeable shifts. If a shift is observed this suggests certain studies are creating a 
bias, which will be interpreted in this context as publication bias. Figure 5 
displays an example of this method. 
Figure 5: Funnel Plot Example (Missing values expected to the right of the mean) 
Study ""me Time poirt 
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*Figure generated using Comprehensive Meta-Analysis V2 
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A convergence can be seen after the fifth study is included. If future 
studies showed a deviation from the converged value, this would indicate 
possible publication bias. 
Lastly, one-study removed analysis can be performed to assess the 
sensitivity per included studies. The benefit of this technique is that each study is 
removed and then a summary is calculated for that one study missing, allowing 
to detect outliers (Borenstein 2009). It is a sensitivity analysis for each study to 
be assessed on grounds of how the summary effects would change if that study 
was not included. Here all statistical methods are the same as outlined 
previously, but each study is excluded to obtain an overall effect. An example of 
this method using the previous data is shown in Figure 6. 
Figure 6: Funnel Plot Example (Missing values expected to the right of the mean) 
StlJ<tI name Time point Statistics w~h study removed Std dill in "",am (95% ell ~h $!ud)I removed 
Point 
Standard Variance Lower ~mi! Upper limit ZV.lue pVaIue -8.00 -4.00 0.00 4.00 8.00 error 
Study A 1 week -1.033 0314 0.088 ·1.648 -0.417 -3286 0.001 
SludyA 1 Post-heatm -1 174 0.403 0.162 -1863 -0.384 -2.814 0.004 
Study B 1 week ·1.819 0.718 0.515 -3225 -0.412 -2.534 DOll 
Study C 1 hour -1908 0595 0353 -3073 -0.743 -3.210 0.001 
Study D , month -1673 0494 0.244 -2.641 -0.705 -3387 0.001 
*Figure generated using Comprehensive Meta-Analysis V2 
In this example, the summary effect displayed next to each study excluded 
varies dramatically. The effects and confidence intervals are not consistent as 
would be hoped for. However, this example uses only five studies so excluding 
one will have more impact than would be expected in a typical meta-analysis 
having many studies. The idea is if one or two studies generate a very different 
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summary effect those studies should be scrutinized to assess if they should be 
included or not. 
Comprehensive Meta Analysis V2.2.050 software was used to perform all 
previous outlined effects, tests, and plots. This software was created by Michael 
Borenstein, Larry Hedges, Julian Higgins, and Hannah Rothstein under a grant 
by the National Institutes of Health (Borenstein M 2009). 
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RESULTS 
Data Search Results 
The search returned 469 hits which were collected and saved in a 
Microsoft Excel spreadsheet for assessment. To determine inclusion or exclusion 
into the meta-analysis, abstracts were read first to see if all the inclusion criteria 
were met as outlined in the methodology section. Reasons for a studies removal 
were then documented. If the study appeared relevant the article was read and 
values were obtained. A total of 232 articles did not have a placebo group and 
could be removed immediately. Excluded studies where placebos were not used 
included physical therapy, various exercise programs, physiotherapy, yoga, 
educational programs, wait list, consultation, and standard or primary care. 
Studies were considered not relevant to the research question when they did not 
evaluate the lower back region, did not measure low back pain using pain scales 
such as the visual analogue score (VAS) or numeric rating scale (NRS-11), or 
only used outcomes such as quality of life (QOL) or similar scores not 
subjectively measuring pain. Studies were also classified as not relevant if they 
were not randomized controlled trials. Other studies were further excluded 
because they were in a language other than English, which made it difficult to 
clearly determine if the study matched the research questions. 
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Many articles were excluded because vital measurements on the placebo 
were not available. Rather, interventions directly compared to placebo were most 
widely reported for the relevant studies and measures for placebo were not 
noted. Four articles matched the inclusion criteria but were mere protocols for 
future studies to be performed. Lastly, 42 studies had to be excluded because 
one or more pre-post measurement to derive placebo effect sizes was missing. A 
few only provided relevant values graphically without a standard deviation for the 
placebo group. After all articles had been reviewed, 50 articles or 11 % of the 
retrieved articles remained for the analysis. 
The placebos in this data set were of the following: unspecified placebo, 
distilled water, placebo nasal spray, isotonic saline solution, spinal saline 
injection with transdermal placebo, and "sham" therapies, which consisted of low-
intensity pulse, electrotherapy, acupuncture, or transcutaneous electrical nerve 
stimulation (TENS). 
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Search Items: (low back pain or LBP) and (Randomized clinical trial or randomised clinical trial 
or randomized controlled trial or randomised controlled trial or RCT) and (placebo or control 
group or control) and human species and article type in (Clinical Trial, Randomized Controlled 
Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, 
Phase IV, Controlled Clinical Trial, Multicenter Study) and publication date from 2000101/01 to 
2010103/01. 
I MedlinelPubMed = 469 total I 
I Placebo-controlled: 232 I 
Reason for article exclusion: 117 
• Study not relevant 58 
• No back pain measure 20 I 115 I • Measure not relevant 39 
Reason for article exclusion: • • Foreign Language I 92 I • Future study protocol 
Insufficient data for pre-post 
effect sizes: 42 
, 
I 
Final Sample Size: 
I 50 
Figure 7: Trial search and results 
Included studies came from the following journals: Academic Emergency 
Medicine, Acupuncture in Medicine (3), American Journal of Medicine, American 
Journal of Physical Medicine and Rehabilitation, Anesthesiology, Clinical Journal 
of Pain (2), Clinical Orthopedics and Related Research, Clinical Rehabilitation, 
Clinical Therapeutics, European Journal of Neurology, European Review for 
Medical and Pharmacological Sciences, European Spine Journal, International 
Journal of Clinical Practice, Journal of Alternative and Complementary Medicine, 





Physiological Therapeutics, Journal of the Medical Association of Thailand, The 
Journal of Pain (4), Journal of Rheumatology, Journal of the American Medical 
Association, Joint Bone Spine, Pain (2), Pain Research and Management, 
Pharmacological Reports, Psychosomatics, Rheumatology, and Spine (7). All 
included articles are listed in the meta-analysis included articles section at the 
end. 
VAS Results 
The majority of the data obtained were paired group means. Since there 
were several time periods in the studies, they were grouped accordingly. Studies 
after treatment in the same day were grouped as post-treatment, while studies 
greater than one day but less than one week were classified as less than one 
week. Some studies recorded measurements at 14 days, while others were 
labeled as two weeks. In these situations they were considered the same and 
sub-grouped together. Table 7 shows the VAS effect difference in means. Post-
treatment and three months had the most number of studies with ten each, while 
some measurement times only had one study included in that effect size 
computation. 
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Table 7: VAS Effect Difference in Means (correlations set to 0.68) 
VAS Difference in Means 
Total 
Difference Standard Lower Upper #of Sample 
Time in means Error Variance Limit Limit Z-Value p-Value studies Size 
post-treat -15.754 4.283 18.348 -24.150 -7.359 -3.678 0.000 10 242 
< 1 week -20.292 11.512 132.531 -42.855 2.272 -1.763 0.078 4 117 
1 week -15.313 7.821 61.163 -30.641 0.015 -1.958 0.050 3 52 
10 days -4.700 1.403 1.969 -7.450 -1.950 -3.349 0.001 1 169 
2 weeks 0.300 2.526 6.380 -4.651 5.251 0.119 0.905 1 48 
3 weeks -9.399 7.742 59.939 -24.573 5.775 -1.214 0.225 2 124 
1 month -11.964 8.289 68.716 -28.211 4.283 -1.443 0.149 5 197 
6 weeks -4.482 3.648 13.305 -11.632 2.667 -1.229 0.219 2 117 
2 months 0.900 2.666 7.109 -4.326 6.126 0.338 0.736 1 48 
3 months -16.465 4.202 17.657 -24.701 -8.229 -3.918 0.000 10 647 
4 months -5.000 5.814 33.800 -16.395 6.395 -0.860 0.390 1 20 
6 months -16.356 5.718 32.697 -27.563 -5.149 -2.860 0.004 5 152 
9 months -18.000 3.280 10.756 -24.428 -11.572 -5.489 0.000 1 45 
1 year -9.000 3.175 10.083 -15.224 -2.776 -2.834 0.005 1 108 
Overall* -14.610 2.640 6.969 -19.784 -9.435 -5.534 0.000 30 1328 
Overall** -14.584 2.601 6.763 -19.681 -9.487 -5.608 0.000 30 1324 
* Overall effect uSing first measurement time 
** Overall effect using mean of selected time points 
Since pre- and post-correlations were not available for any of these 
studies, the correlation estimate used was based on the pre- and post- effects 
obtained. The pre-post effect correlation was found to be 0.68 and used as the 
initial value. 
As shown in Figure 8, the difference in means appears to fluctuate and the 
width of the 95 percent confidence intervals is very large for some measurement 
times and smaller for others. This is most likely due to the fact that several 
measurement times include less than a few studies. 
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Figure 8: VAS of the placebo effect over 1 year, p = 0.68 
















VAS Mean Difference Over 1 Year 
rho = 0.68 
...... Difference in means 
_ Lower Limit 
-'-Upper Limit 
Measurement times that include less than four studies will be excluded 
from investigation, as it would not be reasonable to make inferences about what 
the expected placebo effect might be in low back pain for a period that included 
only a few studies. The validity of those results could easily be questioned. 
Table 8 summarizes the results for all measurement times with four or 
more studies. The difference in means ranges from -20.292 to -11 .964. All 
periods are statistically significant at the 0.005 percent level except less than one 
week and one month. 
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Table 8: VAS Effect Difference in Means (correlations set to 0.68) 
VAS Difference in Means 
Total 
Difference Standard Lower Upper #of Sample 
Time in means Error Variance Limit Limit Z-Value p-Value studies Size 
post-treat -15.754 4.283 18.348 -24.150 -7.359 -3.678 0.000 10 242 
< 1 week -20.292 11.512 132.531 -42.855 2.272 -1.763 0.078 4 117 
1 month -11.964 8.289 68.716 -28.211 4.283 -1.443 0.149 5 197 
3 months -16.465 4.202 17.657 -24.701 -8 .229 -3.918 0.000 10 647 
6 months -16.356 5.718 32.697 -27.563 -5.149 -2.860 0.004 5 152 
Overall* -15.553 2.735 7.478 -20.913 -10.194 -5.688 0.000 28 1150 
Overall* * -15.204 2.732 7.461 -20.558 -9.850 -5.566 0.000 28 1146 
* Overall effect uSing first measurement time 
** Overall effect using mean of selected time points 
As shown in Figure 9, the effects are somewhat constant for these 
periods. The confidence intervals are narrower for post-treatment and three 
month follow-up 
Figure 9: VAS of the placebo effect over 1 year, p = 0.68 (times evaluated) 
VAS Mean Difference 
10.000 
rho = 0.68 
0.000 









post-treat < 1 week 1 month 
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_ Lower Limit 
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times. This is primarily due to the fact they include ten studies which incorporate 
over 200 each, while the others do not. 
To assess the sensitivity of the unknown correlation, a more conservative 
estimate of 0.34 was used. As shown in Table 9, the estimates did not change 
much compared to the initial estimate of 0.68. 
Table 9: VAS Effect Difference in Means (correlations set to 0.34) 
VAS Difference in Means 
Total 
Difference Standard Lower Upper #of Sample 
Time in means Error Variance Limit Limit Z-Value p-Value studies Size 
post-treat -15.743 4.100 16.807 -23.778 -7.708 -3.840 0.000 10 242 
< 1 week -20.225 11.489 132.001 -42.743 2.294 -1.760 0.Q78 4 117 
1 month -12.041 7.719 59.579 -27.169 3.088 -1.560 0.119 5 197 
3 months -16.473 4.402 19.375 -25.100 -7.846 -3.742 0.000 10 647 
6 months -16.368 5.606 31.423 -27.355 -5.381 -2.920 0.004 5 152 
Overall* -15.525 2.724 7.418 -20.863 -10.187 -5.700 0.000 28 1150 
Overall** -15.167 2.737 7.491 -20.532 -9.803 -5.542 0.000 28 1146 
* Overall effect uSing first measurement time 
** Overall effect using mean of selected time points 
Since the values in Table 9 are similar to Table 8, and the original 
estimate was based on the available data, 0.68 was used in the remainder of the 
analysis. 
The first measurement observed per study, such as post-treatment, less 
than one week, one month, three months, or six months was used to assess 
heterogeneity amongst the studies. This resulted in 28 studies used as two of the 
studies did not use one of the previously indicated time points. The Q value 
obtained was 784.36 (df=27) and had a p-value of 0.000. Since the test was 
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performed at the five percent significance level, the null hypothesis was rejected 
and assumption that studies do not share a common effect size was concluded. 
The computed [2 statistic equaled 96.6%, suggesting the observed 
variance was real. Together these statistics suggest that the studies do have 
some noticeable heterogeneity in the effect sizes (Borenstein 2009). 
Figure 10: VAS Forest Plot 
VAS Forrest Plot 
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The forest plot in Figure 10 confirms what was found from the [2 statistic, 
as many of the confidence intervals do overlap. The studies might be similar, but 
the average effects per study range from -58 to +3.4 expressed on the 100mm 
scale. 
Publication bias was assessed as shown in Figure 11. There were a few 
studies with large standardized differences in means toward the bottom of the 
plot with no observations compensating on the right which suggested some 
asymmetry. However, the standardized imputed effect using the trim and fill 
algorithm did not change much compared to the original effect. 
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Since the imputed effect overlaps the original estimate it is believed from 
this method that publication bias is minimal. 
Figures 12 and 13 show the funnel plot on the raw difference scale. 
Figure 12: Looking for missing values to right of the mean - Difference in Means 
Funnel Plot of Standard Error by Difference in means 
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2 • Imputed studies 
3 <> Summar)' effect 
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Figure 13: Looking for missing values to left of the mean - Difference in Means 
Funnel Plot of Standard Error by Difference in means 
Observed sludies 
2 • • Imputed studies 
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It was expected that publication bias would come from the right of the 
mean as studies reported smaller effects or non-significant results would be 
under-represented. However, the trim and fill algorithm did not have any 
imputations moving from the left side of the line to the right as shown in Figure 
12. Trim and fill from the right to left did impute five studies to obtain symmetry. 
This would suggest studies not included in this sample that have been missed 
are actually larger effect studies, if the sample obtained was generated by 
random selection. Since the imputed effect and original effect overlap, publication 
bias is assumed to be minimal. 
The last investigation of publication bias for the VAS data was the 
cumulative effect plot where studies were included based on how they were 
entered into the software. 
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Figure 14: Cumulative Effect for VAS 
Study name, Time point 
Koopman 2.000 
Gabis L 1 10.000 
Vorsanger 10.000 
Kennedy S 1.000 
Konstantino 1. ODD 
Hale ME 10.000 
Aminmanso 100.0. 
Dobrogows 7000 
B ertaianffy 1.000 
KetenciA 1 2.000 
KerrDP 12.00.0. 
Tuzun F 2.000 
Gabis L 2 1.000 
Mauro GL 1.000 
Dickens C 7000. 
Lauretti GR 2.000 
D i az Arribas 1.000 
Inoue M 1.000 
Talazai SI 7000 
Wiruchpong 1.000 
Arden NK 10.000 
Ketenci A 2 7000 
Pauza KJ 12.0.00 
Leibing E 10.000 
Leclaire R 7000 
Colacott EA 1. 0.00 
NathS 12.000 
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*Figure generated using Comprehensive Meta-Analysis V2 
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Figure 14 does not show any shifts in the computed effect when each 
study is included to generate the summary effect. The time points are indicators 
of the measurement time, such as "1" meaning post-treatment, etc. 
The failsafe N computed for standardized mean effect was 2639, meaning 
there would need to be 2639 excluded studies included in the study before the p-
value would become non-significant at the five percent alpha level. The failsafe N 
for the raw differences was 7181 stUdies needed to generate a non-significant p-
value. Both of these large values serve as just another bit of evidence to 
conclude a lack of publication bias for the VAS data. 
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One-study removed analysis was performed. From Figure 15, it was 
expected the Lauretti study would show outlying effects thus generate a different 
summary effect than the others including it. However, as shown below that was 
not the case. Complete review of the Lauretti article, found it to be a valid 
included article which met all the previous detailed inclusion criteria. The placebo 
was an injection type for post-operative gynecological surgery on the lower spinal 
region. One reason for the difference is this study only had 12 participants where 
the average was 45 participants. This is another reason why excluding the study 
did not have a profound effect on the overall summary effect. 
Figure 15: One-study removed for VAS 
Study name T ima point Statiotic. with study removed Std clift in meaN (95% OJ with .tudy removed 
Point Standatd Variance Lows limit Upper limit Z-Value error p-Value -1.50 -0.75 0.00 0_75 1.50 
Koopman 2000 -0.736 0.111 0.012 ·0.954 -0.518 -6.606 0000 
Gabi, L 1 10.000 -0.716 0.113 0.013 ·0938 -0.495 -6.349 0.000 
Vorsanger 10000 -0.731 0119 0014 -0965 -0498 -6.137 0.000 
Kennedy S 1.000 -0.620 0.104 0.011 -0.824 -0.416 -5.959 0.000 
Konstantino 1.000 -0.715 0.112 0.013 -0.935 -0.494 -6.355 0.000 
Hale ME 10.000 -0.612 0.097 0.009 -0803 -0422 -6.288 0.000 
Aminmanso 1.000 -0.696 0.112 0.013 ·0.916 -0.476 -6.206 0.000 
Dobrogows 7000 -0.639 0.106 0.011 -0847 -0.430 -6.001 0.000 
Bertalanlly 1000 ·0735 0112 0.013 ·0.955 -0.515 -6.550 0.000 
KetenclA 1 2.000 -0.732 0.113 0.013 ·0.953 -0.511 -6491 0000 
KenDP 12.000 -0.715 0.114 0.013 ·0.938 -0492 -6.285 0.000 
TU2Un F 2.000 -0.668 0.107 0.012 ·0.878 -0.457 ·6.214 0.000 
Gabi' L 2 1.000 -0.700 0.112 0.013 ·0.920 -0.481 -6.256 0.000 
Mauro GL 1.000 -0684 0.111 0.012 -0.902 -0.467 -6.159 0.000 
Dickens C 7.000 -0735 0.112 0.013 -0.955 -0.515 -6.549 0000 
Lauretti GR 2.000 -0.652 0.108 0.012 -0.864 -0.440 -6.024 0.000 
D f dZ Arribas 1 000 -0.708 0.115 0.013 -0.933 -0.484 -6.179 0000 
Inoue M 1.000 -0.715 0113 0.013 -0.936 -0.494 -6.338 0.000 
Tala,al51 7.000 -0.732 0.112 0.013 -0952 -0.511 -6.510 0000 
Wiruchpong 1.000 -0.712 0.113 0.013 -0.934 -0.490 -6.279 0.000 
Arden NK 10.000 -0.734 0.117 0.014 -0.962 -0.505 -6.287 0.000 
Ketenei A 2 7 000 -0701 0.114 0.013 -0925 -0.478 -6.159 0000 
Pauza KJ 12000 -0.721 0.113 0.013 -0.943 -0498 -6.354 0.000 
Leibing E 10.000 -0.704 0114 0013 ·0.927 -0482 -6.200 0000 
Leclaire R 7.000 -0.733 0.113 0.013 ·0.954 -0.511 -6.492 0000 
Colaeott EA 1.000 -0723 0112 0.013 ·0943 ·0502 -6435 0000 
Rossini 7000 -0.705 0.111 0.012 ·0.924 -0.487 -6.338 0.000 
NathS 12.000 -0714 0113 0.013 ·0935 -0493 -6343 0000 
Ruoll GE 10.000 -0.733 0.117 0.014 ·0.961 -0.504 -6.281 0.000 
-0.704 0.110 0.012 -0.919 -0.489 -6.411 0000 
*Figure generated using Comprehensive Meta-Analysis V2 
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NRS-11 Results 
There were 11 unique studies with a total of 477 combined observations. 
Similar to the VAS measurements, pre-post correlations from effects were not 
available. An estimate of 0.42 was used based on the available pre- and post-
effect sizes. 
Table 10: NRS-11 Effect Difference in Means (correlations set to 0.42) 
NRS-ll Difference in Means 
Total 
Difference Standard Lower Upper #of Sample 
Time in means Error Variance Limit Limit Z-Value p-Value studies Size 
post-treat -0.489 0.635 0.403 -1.733 0.756 -0.770 0.441 2 53 
1 week -1.188 0.661 0.437 -2.483 0.108 -1.797 0.072 3 92 
2 weeks -0.621 0.285 0.081 -1.180 -0.062 -2.176 0.030 1 17 
3 weeks -0.140 0.438 0.192 -0.998 0.718 -0.320 0.749 1 18 
1 month -1.920 0.979 0.959 -3.839 -0.001 -1.961 0.050 5 97 
5 weeks 0.000 0.723 0.522 -1.416 1.416 0.000 1.000 1 17 
6 weeks -1.201 0.236 0.056 -1.664 -0.739 -5.092 0.000 2 61 
2 months -1.000 0.288 0.083 -1.565 -0.435 -3.471 0.001 1 77 
3 months -2.136 0.436 0.190 -2.991 -1.280 -4.894 0.000 3 226 
6 months -1.511 0.500 0.250 -2.491 -0.531 -3.023 0.003 2 102 
12 months -1.058 0.750 0.562 -2.528 0.412 -1.410 0.158 2 102 
Overall* -1.541 0.376 0.141 -2.277 -0.804 -4.101 0.000 11 477 
Overall** -1.514 0.355 0.126 -2.209 -0.819 -4.270 0.000 11 478 
• Overall effect uSing first measurement time 
•• Overall effect using mean of selected time points 
Most of the measurement times were investigated by only a few studies. 
Month one was in the most studies, with five. Given the limited number of 
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studies, the NRS-11 measurements will only include the first measurement 
recorded per study in the remaining meta-analysis. From Table 10, using the first 
measurement time per study had a statistically significant difference in means, 
with a point estimate of -1.54 with a 95 percent confidence interval of -2.277 to 
-0.804. A more conservative correlation of 0.21 was also tested for sensitivity and 
found to not modify the overall effect much with a point estimate of -1.54 with a 
95 percent confidence interval of -2 .307 to -0.766. 
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Testing the heterogeneity amongst the study effects revealed a Q statistic 
of 108.15 (df=1 0) and a p-value < 0.001 . Since the test was performed at the five 
percent significance level, the null hypothesis was rejected and it was concluded 
that studies do not share a common effect size. 
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The ]2 statistic was 90.75% suggesting that most of the observed variance 
was probably real. 
The forest plot in Figure 17 shows somewhat consistent effects across 
studies without including the Friedman study. On review, the Friedman study's 
inclusion criteria were validated. Placebo values obtained were for radicular low 
back pain. Interestingly, this study included 41 patients whereas the Lauretti 
study was shown to have a very small sample. 
Figure 17: NRS-11 forest plot 
NSR-11 Forrest Plot 
Study name Time point Difference in means and 95% CI 
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A one-study removed analysis was then performed. Figure 18 shows the 
overall effect is smaller with the Friedman study removed. This study was still 
within the range of most of the other one-study removed intervals. 
Figure 18: NRS-11 Forest Plot - One Study Removed 
NSR-11 Forrest Plot - One Study Removed 
Study name Time point 
Manchikanti L 10.000 
Costa, LO. 12.000 
Cohen SP 1 7.000 
Cohen SP 2 7.000 
Webster LR 10.000 
Gale GO 3.000 
Lee P8 1000 
Katz J 8000 
Friedman 8W 7000 
Guerreiro da Silva J8 1.000 
Ruoff GE 10.000 
Difference in means (95% 
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The Placebo Effect in Low Back Pain: A Meta Analysis 
Publication bias does not appear to be an issue here. Figures 19 and 20 
show what the effect would be after the trim and fill algorithm is run from both the 
left and right side. Similar to the VAS results the bias appears to be from larger 
more significant studies missing rather than smaller non-significant studies 
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missing. The difference between the imputed shift and the original estimate does 
not warrant strong publication bias. 
Figure 19: Looking for missing values to right of the mean - Difference in Means 
Funnel Plot of Standard Error by Difference In means 
0.0 
0 Observeo studies 
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Figure 20: Looking for missing values to left of the mean - Difference in Means 
Funnel Plot of Standard Error by Difference in means 
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The cumulative effect for NRS-11 shown in Figure 21 appears to have a 
shift at the Friedman study, indicating a possible bias. 
Figure 21: Cumulative Effect for NRS-11 
M del s .... , T' . Cu Ia' . . CumulaliYe o tuuy name' """ point mu tIve statlSbCs sample size Cumulative difle,ence in means (95% a I 
Point 
Manchikanti 10.000 ·2.600 
Costa. LO. 12000 ·1.796 
Cohen SP 1 7 000 ·1.646 
Cohen SP 2 7.000 ·1.319 
Webste, LR 1 O. 000 ·1.585 
Gale GO 3.000 ·1.339 
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F,iedman 7.000 ·1.729 0.000 299 
Gue"ei,o da 1.000 ·1.550 0.001 333 
Ruoff GE 10.000 -1.541 0.000 477 
·10.00 ·5.00 0.00 
Random -1.541 0.000 -+-















The failsafe N was computed to be 501, meaning at least 500 excluded 
studies would need to be included before the p-value would exceed the five 
percent alpha level. 
Table 11 summarizes the raw mean effects obtained for both the VAS and 
NRS-11 scales. All studies are highly significant with p-value < 0.001. 
Table 11: Placebo Effect Difference in Means (100 mm scale) 
Total 
Pain Correlation Difference Lower Upper #of Sample Fail-Safe 
Scale Used in means Limit Limit p-Value studies Size N 
VAS 0.680 -15.553 -20.913 -10.194 0.000 28 1150 7178 
VAS 0.340 -15.525 -20.863 -10.187 0.000 28 1150 4874 
NRS-ll 0.420 -1.523 -2.250 -0.795 0.000 11 477 495 
NRS-ll 0.210 -1.537 -2.307 -0.766 0.000 11 477 418 
The unknown correlation did not appear sensitive using the data estimated 
initial values compared to the more conservative correlation estimates. 
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Neither in the more robust VAS study nor the NSR-11 study was 
convincing evidence that publication bias was invalidating the results. In most 
cases, publication bias will result from smaller non-significant studies as they are 
more likely to be left in the "file drawer." However, in both cases the trim and fill 
algorithm did not need any bias adjustment to the right of the mean suggesting 
that studies of higher effect were possibly excluded. Table 12 shows the adjusted 
difference in means for studies excluding larger effect sizes. Comparing Tables 
11 and 12 show an even larger expected placebo effect than was observed using 
the studies found. However, the observed summary effects are deemed more 
appropriate to draw interferences from rather than the ones derived using the 
trim and fill method. While the differences are larger they are not large enough to 
invalid the study. This just gives support that the studies sampled were 
representative of the population of studies and the trim and fill imputations did not 
show a highly sensitive effect. 
Table 12: Trim and Fill to the Left Placebo Effect Difference in Means 
Total 
Pain Correlation Difference Lower Upper #of Sample 
Scale Used in means Limit Limit p-Value studies Size 
VAS 0.680 -19.203 -24.316 -14.090 0.000 28 1150 
VAS 0.340 -19.167 -24.244 -14.090 0.000 28 1150 
NRS-ll 0.420 -2.194 -2.935 -1.453 0.000 11 477 
NRS-ll 0.210 -2.180 -2.937 -1.424 0.000 11 477 
In addition the raw scales reported which are believed to be beneficial for 
interpretation for those using them, standardized measures were also computed. 
59 
However, standardized measures allow both the VAS and NRS-11 scales to be 
compared, in addition to accounting for subjective biases from the extreme end 
labels (Wewers, et al. 1990, Hartrick, et al. 2003). 
Table 13 summarizes the standardized difference in means and shows 
that the correlations used were not sensitive to the overall mean effects. All 
values were highly statistically significant with p-values < 0.001. 
Table 13: Placebo Effect Standardized Difference in Means 
Total 
Correlation Difference Lower Upper #of Sample Fail-Safe 
Pain Scale Used in means Limit Limit p-Value studies Size N 
VAS 0.680 -0.699 -0.917 -0.480 0.000 29 1168 2721 
VAS 0.340 -0.762 -1.002 -0.522 0.000 29 1171 1722 
NRS-ll 0.420 -0.659 -0.946 -0.373 0.000 11 477 294 
NRS-ll 0.210 -0.689 -1.001 -0.377 0.000 11 477 231 
The VAS and NRS-11 standardized difference in means is almost the 
same suggesting there is a consistent placebo effect regardless of the pain scale 
used for both scales at approximately -0.70 with confidence limits roughly -1.0 to 
-0.45. 
Using the trim and fill algorithm to the left of the mean does not change 
the estimates much for either pain scale as shown in Table 14. As stated 
previously, the trim and fill algorithm from the right yields the original results as 
shown in Table 13. 
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Table 14: Placebo Effect Standardized Differences - Trim and Fill to the Left 
Total 
Correlation Difference Lower Upper #of Sample 
Pain Scale Used in means Limit Limit p-Value studies Size 
VAS 0.680 -0.704 -0.919 -0.489 0.000 29 1168 
VAS 0.340 -0.940 -1.203 -0.677 0.000 29 1171 
NRS-ll 0.420 -0.747 -1.055 -0.438 0.000 11 477 
NRS-ll 0.210 -0.784 -1.117 -0.451 0.000 11 477 
While Hrobjartsson and Gotzsches' studies found a placebo standardized 
mean effect of -0.25 (-0.35, -0.16) for general pain, the placebo effect for low 
back pain suggests a higher effect of -0.70 (-0.92, -0.48) using the VAS scale. 
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CONCLUSIONS 
From the available data, the placebo effect in lower back pain trials 
appears to be consistent from post-treatment to six months based on the visual 
analogue scale (VAS). The quantitative effect past six months cannot be 
addressed as there are only two studies that obtained measurements past that 
time. The NRS-11 did not have enough power to make inferences over time so a 
general effect was assessed using the first measurement past baseline. 
The literature has noted the correlations for pre- and post-measurements 
are usually not reported in studies because they are usually not relevant to the 
study at hand. This study used a derived expected correlation from pre and post 
effects that were available. Then the analysis was performed again with a more 
conservative estimate. Differences in the correlations were not shown to 
significantly alter the summary effects. 
Neither in the more robust VAS study nor the NSR-11 study was 
convincing evidence of publication bias shown to invalidate the results. In most 
cases, publication bias will result from smaller non-significant studies as they are 
more likely to be left in the "file drawer". However, in both cases the trim and fill 
algorithm did not need any bias adjustment to the right of the mean suggesting 
that studies with larger effects were possibly excluded. Trim and fill bias to the 
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left did impute values for both the VAS and NRS-11 but the imputed summary 
effect largely overlapped the original effect in both cases leading to the 
conclusion of little publication bias. 
One study in each pain scale was initially suspected to be non-relevant as 
they appeared to deviate from the other studies. However, after reviewing the 
articles and performing one-study-removed forest plots it was decided to be 
appropriate to include the articles. 
From the literature there does appear to be a highly statistically significant 
placebo effect in low back pain studies. It was established that the expected VAS 
difference in means was -15.6 (-20.9, -10.2) with a p-value < 0.001 and the NRS-
11 difference in means to be -1.5 (-2.3, -0.8) with a p-value < 0.001. 
Standardizing the measurements lead to a VAS expected standardized mean 
difference of -0.70 (-0.92, -0.48) with a p-value < 0.001 and a NRS-11 
standardized mean difference of -0.66 (-0.95, -0.37). Both effects appear 
extremely consistent regardless of scale. 
The placebo effect in low back pain is shown to be higher than general 
pain assessment of -0.25 (-0.35, -0.16). Using the estimates obtained in th is 
study should allow future investigations on low back pain to have certain 
expectations of the placebo arm, whereas previously this was uncertain. 
Future work will involve contacting authors where studies were not able to 
be included because vital metrics were not available in the article. In addition, 
unpublished studies may be known to researchers performing such studies and 
will be inquired about as well. Searching for posters and meetings online has 
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been posed as another way to find smaller studies yet to be published. Lastly, 
searching the Cochrane Library using the same criteria used for the PubMed is 
expected to help generate more relevant studies to increase the power of the 
computed summary effects. 
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